Valeritas (NSDQ:VLRX) touted today the publication of a retrospective analysis showing that adults with Type 2 diabetes experienced improved glycemic control using the V-Go wearable insulin delivery device and a physician-driven titration algorithm.
The proof-of-concept study was designed to assess the safety and efficacy of a doctor-driven insulin titration algorithm in adults who were prescribed V-Go. Researchers evaluated the participants’ clinical outcomes after four months.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas touts use of insulin delivery device with physician-driven titration algorithm appeared first on MassDevice.
from MassDevice https://ift.tt/2PWZHZM
Cap comentari:
Publica un comentari a l'entrada